γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers

Nuša Trošt1,2, Samuel Peña-Llopis2, Sajjan Koirala3

  • 1Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Oncotarget
|November 12, 2015
PubMed

Insights

γKlotho, a protein, is overexpressed in triple-negative breast cancer (TNBC), driving tumor growth and survival. Targeting γKlotho may offer new therapeutic strategies for TNBC patients, particularly those with oxidative stress vulnerabilities.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) has high recurrence rates and lacks targeted therapies.
  • Identifying TNBC subgroups with specific molecular features is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of γKlotho in TNBC.
  • To determine if γKlotho can be a therapeutic target for TNBC.

Main Methods:

  • γKlotho expression analysis in TNBC tissues and cell lines.
  • Functional studies involving γKlotho depletion in TNBC cells.
  • Assessment of cell survival, cell cycle, apoptosis, ERK activation, and oxidative stress.

Main Results:

  • γKlotho is overexpressed in over 60% of TNBCs, correlating with poor prognosis.
  • γKlotho promotes TNBC cell growth and is essential for cell survival.
  • γKlotho depletion causes ERK activation, cell cycle arrest, apoptosis, and increased oxidative stress.
  • TNBC cells become dependent on γKlotho for survival in oxidative environments.

Conclusions:

  • γKlotho is a potential biomarker for identifying TNBC patients who may benefit from oxidative stress-modulating therapies.
  • γKlotho represents a novel therapeutic target for a subset of TNBCs.

Related Concept Videos